Confronting antifungal resistance, tolerance, and persistence: advances in drug target discovery and delivery systems.

[1]  Min Zhang,et al.  Structural and mechanistic insights into fungal β-1,3-glucan synthase FKS1 , 2023, Nature.

[2]  M. Zimmerman,et al.  Macrophage internalization creates a multidrug-tolerant fungal persister reservoir and facilitates the emergence of drug resistance , 2023, Nature Communications.

[3]  I. Whang,et al.  Antimicrobial Peptide Octominin-Encapsulated Chitosan Nanoparticles Enhanced Antifungal and Antibacterial Activities , 2022, International journal of molecular sciences.

[4]  Wei Du,et al.  Calcofluor white-cholesteryl hydrogen succinate conjugate mediated liposomes for enhanced targeted delivery of voriconazole into Candida albicans. , 2022, Biomaterials science.

[5]  Yang Chen,et al.  Gold Nanoparticles for Skin Drug Delivery. , 2022, International journal of pharmaceutics.

[6]  J. Day,et al.  Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going? , 2022, Drugs.

[7]  Paul M. Magwene,et al.  Uncontrolled transposition following RNAi loss causes hypermutation and antifungal drug resistance in clinical isolates of Cryptococcus neoformans , 2022, Nature Microbiology.

[8]  B. Zwaan,et al.  Tackling the emerging threat of antifungal resistance to human health , 2022, Nature reviews. Microbiology.

[9]  Jinjin Shi,et al.  Augmenting the Precise Targeting of Antimicrobial Peptides (AMPs) and AMP‐Based Drug Delivery via Affinity‐Filtering Strategy , 2022, Advanced Functional Materials.

[10]  Yipeng Wang,et al.  Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug‐resistant infections , 2022, Medicinal research reviews.

[11]  Z. Lewis,et al.  DC-SIGN targets amphotericin B-loaded liposomes to diverse pathogenic fungi , 2021, Fungal biology and biotechnology.

[12]  G. Fabbrocini,et al.  New Applications of Photodynamic Therapy in the Management of Candidiasis. , 2021, Journal of fungi.

[13]  Matthew J. O’Meara,et al.  Leveraging machine learning essentiality predictions and chemogenomic interactions to identify antifungal targets , 2021, Nature Communications.

[14]  S. Helaine,et al.  Antibiotic persistence and tolerance: not just one and the same. , 2021, Current Opinion in Microbiology.

[15]  Alexander Bruch,et al.  RNA-based therapeutics to treat human fungal infections , 2021, Trends in Microbiology.

[16]  W. Ramakrishna,et al.  Transposons: Unexpected players in cancer. , 2021, Gene.

[17]  Lan-Yan Yang,et al.  Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia. , 2021, Medical mycology.

[18]  K. Chintalacharuvu,et al.  Complexing amphotericin B with gold nanoparticles improves fungal clearance from the brains of mice infected with Cryptococcal neoformans. , 2021, Medical mycology.

[19]  Z. Lewis,et al.  DectiSomes: Glycan Targeting of Liposomal Drugs Improves the Treatment of Disseminated Candidiasis , 2021, bioRxiv.

[20]  L. Angiolella,et al.  Antimicrobial and cytotoxic activity of green synthesis silver nanoparticles targeting skin and soft tissue infectious agents , 2021, Scientific Reports.

[21]  Z. Lewis,et al.  Aiming for a bull’s-eye: Targeting antifungals to fungi with dectin-decorated liposomes , 2021, PLoS pathogens.

[22]  T. Walsh,et al.  Novel antifungal agents in clinical trials. , 2021, F1000Research.

[23]  Ashka Patel,et al.  Salvage Therapy for the Treatment of Mucormycosis , 2021, Current Treatment Options in Infectious Diseases.

[24]  P. Walter,et al.  Moderate levels of 5-fluorocytosine cause the emergence of high frequency resistance in cryptococci , 2021, Nature Communications.

[25]  Yiling Sun,et al.  Platforms for High-Throughput Screening and Force Measurements on Fungi and Oomycetes , 2021, Micromachines.

[26]  M. Nurunnabi,et al.  Delivery strategies of amphotericin B for invasive fungal infections , 2021, Acta pharmaceutica Sinica. B.

[27]  Z. Pan,et al.  Antifungal activity of silver nanoparticles synthesized by iturin against Candida albicans in vitro and in vivo , 2021, Applied Microbiology and Biotechnology.

[28]  M. Shams-Ghahfarokhi,et al.  Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans. , 2021, Bioorganic & medicinal chemistry letters.

[29]  Chengwei He,et al.  The structure-mechanism relationship and mode of actions of antimicrobial peptides: A review , 2021 .

[30]  L. Cowen,et al.  Treatment strategies for cryptococcal infection: challenges, advances and future outlook , 2021, Nature Reviews Microbiology.

[31]  Nicholas A. Peppas,et al.  Engineering precision nanoparticles for drug delivery , 2020, Nature reviews. Drug discovery.

[32]  A. Zinkernagel,et al.  Antibiotic resistance and persistence—Implications for human health and treatment perspectives , 2020, EMBO reports.

[33]  M. Del Poeta,et al.  The Future of Antifungal Drug Therapy: Novel Compounds and Targets , 2020, Antimicrobial Agents and Chemotherapy.

[34]  A. Ibrahim,et al.  Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections , 2020, Journal of fungi.

[35]  Guanghua Huang,et al.  Candida auris: Epidemiology, biology, antifungal resistance, and virulence , 2020, PLoS pathogens.

[36]  Ashutosh Kumar Singh,et al.  Sphingolipidomics of drug resistant Candida auris clinical isolates reveal distinct sphingolipid species signatures , 2020, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[37]  Xiaoyou Wang,et al.  Strategies for Drug Delivery of Deep Fungal Infection: A Review. , 2020, Pharmaceutical nanotechnology.

[38]  S. Reis,et al.  Current Insights on Antifungal Therapy: Novel Nanotechnology Approaches for Drug Delivery Systems and New Drugs from Natural Sources , 2020, Pharmaceuticals.

[39]  G. Reboux,et al.  Azole-resistant Aspergillus fumigatus: A global phenomenon originating in the environment? , 2020, Medecine et maladies infectieuses.

[40]  L. Cowen,et al.  Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond. , 2020, Chemical reviews.

[41]  B. Lazzaro,et al.  Antimicrobial peptides: Application informed by evolution , 2020, Science.

[42]  J. Heitman,et al.  Transposon mobilization in the human fungal pathogen Cryptococcus is mutagenic during infection and promotes drug resistance in vitro , 2020, Proceedings of the National Academy of Sciences.

[43]  S. Mitragotri,et al.  Targeting Strategies for Tissue-Specific Drug Delivery , 2020, Cell.

[44]  Y. Bahn,et al.  Fungal kinases and transcription factors regulating brain infection in Cryptococcus neoformans , 2020, Nature Communications.

[45]  J. Berman,et al.  Drug resistance and tolerance in fungi , 2020, Nature Reviews Microbiology.

[46]  R. Herbrecht,et al.  Antifungal Therapy: New and Evolving Therapies , 2020, Seminars in Respiratory and Critical Care Medicine.

[47]  L. Larson,et al.  Hope on the Horizon: Novel Fungal Treatments in Development , 2020, Open forum infectious diseases.

[48]  Irine Ronin,et al.  Effect of tolerance on the evolution of antibiotic resistance under drug combinations , 2020, Science.

[49]  Zhipeng Chen,et al.  Borneol and poly (ethylene glycol) dual modified BSA nanoparticles as an itraconazole vehicle for brain targeting. , 2019, International journal of pharmaceutics.

[50]  Lianhui Wang,et al.  A lipase-responsive antifungal nanoplatform for synergistic photodynamic/photothermal/pharmaco-therapy of azole-resistant Candida albicans infections. , 2019, Chemical communications.

[51]  J. Heitman,et al.  Epigenetic mechanisms of drug resistance in fungi. , 2019, Fungal genetics and biology : FG & B.

[52]  D. Wishart.  Metabolomics for Investigating Physiological and Pathophysiological Processes. , 2019, Physiological reviews.

[53]  C. Lass‐Flörl,et al.  Antifungal resistance in Aspergillus terreus: A current scenario. , 2019, Fungal genetics and biology : FG & B.

[54]  H. Tsai,et al.  A Double-Edged Sword: Aneuploidy is a Prevalent Strategy in Fungal Adaptation , 2019, Genes.

[55]  L. Majoros,et al.  Synergistic effect of nikkomycin Z with caspofungin and micafungin against Candida albicans and Candida parapsilosis biofilms , 2019, Letters in applied microbiology.

[56]  D. Boulware,et al.  Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. , 2019, The Lancet. Infectious diseases.

[57]  A. Selmecki,et al.  Genome plasticity in Candida albicans is driven by long repeat sequences , 2019, eLife.

[58]  Yingkuan Han,et al.  A novel anti Candida albicans drug screening system based on high-throughput microfluidic chips , 2019, Scientific Reports.

[59]  J. Xie,et al.  Oriented Assembly of Cell-Mimicking Nanoparticles via a Molecular Affinity Strategy for Targeted Drug Delivery. , 2019, ACS nano.

[60]  L. Tell,et al.  High Efficiency Drug Repurposing Design for New Antifungal Agents , 2019, Methods and protocols.

[61]  J. Collins,et al.  Definitions and guidelines for research on antibiotic persistence , 2019, Nature Reviews Microbiology.

[62]  T. Holowka,et al.  Gene Duplication Associated with Increased Fluconazole Tolerance in Candida auris cells of Advanced Generational Age , 2019, Scientific Reports.

[63]  P. Visca,et al.  Activity and Impact on Resistance Development of Two Antivirulence Fluoropyrimidine Drugs in Pseudomonas aeruginosa , 2019, Front. Cell. Infect. Microbiol..

[64]  C. Cuomo,et al.  Genetic Analysis of Candida auris Implicates Hsp90 in Morphogenesis and Azole Tolerance and Cdr1 in Azole Resistance , 2019, mBio.

[65]  J. Xie,et al.  Nanoparticles Targeted against Cryptococcal Pneumonia by Interactions between Chitosan and Its Peptide Ligand. , 2018, Nano letters.

[66]  J. Berman,et al.  Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia , 2018, Nature Communications.

[67]  J. Perfect,et al.  In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus , 2018, Antimicrobial Agents and Chemotherapy.

[68]  Juan Camilo Castrillón-Betancur,et al.  The Interaction of Human Pathogenic Fungi With C-Type Lectin Receptors , 2018, Front. Immunol..

[69]  M. Fisher,et al.  Worldwide emergence of resistance to antifungal drugs challenges human health and food security , 2018, Science.

[70]  C. Moore,et al.  A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species , 2018, Mycoses.

[71]  L. Goldani,et al.  Relationship between intracranial pressure and antifungal agents levels in the CSF of patients with cryptococcal meningitis , 2018, Medical mycology.

[72]  G. M. Gelfuso,et al.  SLN- and NLC-encapsulating antifungal agents: skin drug delivery and their unexplored potential for treating onychomycosis. , 2018, Current pharmaceutical design.

[73]  L. Ries,et al.  Overview of carbon and nitrogen catabolite metabolism in the virulence of human pathogenic fungi , 2018, Molecular microbiology.

[74]  S. Majumdar,et al.  Echinocandins in antifungal pharmacotherapy , 2017, The Journal of pharmacy and pharmacology.

[75]  Felix Bongomin,et al.  Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision , 2017, Journal of fungi.

[76]  L. Cowen,et al.  Molecular Evolution of Antifungal Drug Resistance. , 2017, Annual review of microbiology.

[77]  M. Arendrup,et al.  Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment , 2017, The Journal of infectious diseases.

[78]  L. Myers,et al.  Candida albicans Swi/Snf and Mediator Complexes Differentially Regulate Mrr1-Induced MDR1 Expression and Fluconazole Resistance , 2017, Antimicrobial Agents and Chemotherapy.

[79]  A. Casadevall,et al.  Fungi that Infect Humans , 2017, Microbiology spectrum.

[80]  J. Latgé,et al.  The Fungal Cell Wall: Structure, Biosynthesis, and Function , 2017, Microbiology spectrum.

[81]  G. M. Soliman.  Nanoparticles as safe and effective delivery systems of antifungal agents: Achievements and challenges. , 2017, International journal of pharmaceutics.

[82]  J. Perfect.  The antifungal pipeline: a reality check , 2017, Nature Reviews Drug Discovery.

[83]  A. Tiwary,et al.  High failure rate of transungal drug delivery: need for new strategies. , 2017, Therapeutic delivery.

[84]  J. Perfect,et al.  Central Role of the Trehalose Biosynthesis Pathway in the Pathogenesis of Human Fungal Infections: Opportunities and Challenges for Therapeutic Development , 2017, Microbiology and Molecular Biology Reviews.

[85]  B. Regenberg,et al.  Persistence and drug tolerance in pathogenic yeast , 2016, Current Genetics.

[86]  Aditya K. Gupta,et al.  New Antifungal Agents and New Formulations Against Dermatophytes , 2017, Mycopathologia.

[87]  D. Krysan.  The unmet clinical need of novel antifungal drugs , 2017, Virulence.

[88]  B. Fu,et al.  Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood–brain barrier permeability , 2017, Drug delivery.

[89]  K. Gerdes,et al.  Mechanisms of bacterial persistence during stress and antibiotic exposure , 2016, Science.

[90]  A. Chowdhary,et al.  Multidrug-resistant Candida auris: 'new kid on the block' in hospital-associated infections? , 2016, The Journal of hospital infection.

[91]  L. Cowen,et al.  Antifungal Drugs: The Current Armamentarium and Development of New Agents , 2016, Microbiology spectrum.

[92]  G. L. Meyers,et al.  Systematic functional analysis of kinases in the fungal pathogen Cryptococcus neoformans , 2016, Nature Communications.

[93]  Ernest Giralt,et al.  Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery. , 2016, Chemical Society reviews.

[94]  Nicola Nosengo.  Can you teach old drugs new tricks? , 2016, Nature.

[95]  M. Moazeni,et al.  Time to overcome fluconazole resistant Candida isolates: Solid lipid nanoparticles as a novel antifungal drug delivery system. , 2016, Colloids and surfaces. B, Biointerfaces.

[96]  Ofer Fridman,et al.  Distinguishing between resistance, tolerance and persistence to antibiotic treatment , 2016, Nature Reviews Microbiology.

[97]  B. Alexander,et al.  Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance , 2016, Nature Communications.

[98]  Q. Fang,et al.  Microfluidics for cell-based high throughput screening platforms - A review. , 2016, Analytica chimica acta.

[99]  Mike Tyers,et al.  Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. , 2015, Cell systems.

[100]  M. J. Arellano-Jimenez,et al.  Effect of silver nanoparticles on Candida albicans biofilms: an ultrastructural study , 2015, Journal of Nanobiotechnology.

[101]  N. Khalil,et al.  Bovine Serum Albumin Nanoparticles Containing Amphotericin B: Characterization, Cytotoxicity and In Vitro Antifungal Evaluation. , 2015, Journal of nanoscience and nanotechnology.

[102]  Zhen Zhao,et al.  Establishment and Dysfunction of the Blood-Brain Barrier , 2015, Cell.

[103]  D. Sanglard,et al.  Defining the frontiers between antifungal resistance, tolerance and the concept of persistence. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[104]  Yong-nian Shen,et al.  The Rpd3/Hda1 family of histone deacetylases regulates azole resistance in Candida albicans. , 2015, The Journal of antimicrobial chemotherapy.

[105]  J. Slightom,et al.  Generation of Broad-Spectrum Antifungal Drug Candidates from the Natural Product Compound Aureobasidin A. , 2015, ACS medicinal chemistry letters.

[106]  B. Alexander,et al.  Antifungal activity of compounds targeting the Hsp90-calcineurin pathway against various mould species. , 2015, The Journal of antimicrobial chemotherapy.

[107]  S. Córdoba,et al.  Comparison of Different In Vitro Tests to Detect Cryptococcus neoformans Not Susceptible to Amphotericin B , 2015, Mycopathologia.

[108]  C. Myers,et al.  Unraveling the Biology of a Fungal Meningitis Pathogen Using Chemical Genetics , 2014, Cell.

[109]  Alistair J. P. Brown,et al.  Metabolism in fungal pathogenesis. , 2014, Cold Spring Harbor perspectives in medicine.

[110]  J. Galgiani,et al.  Modeling nikkomycin Z dosing and pharmacology in murine pulmonary coccidioidomycosis preparatory to phase 2 clinical trials. , 2014, The Journal of infectious diseases.

[111]  G. Fetih,et al.  Comparative topical delivery of antifungal drug croconazole using liposome and micro-emulsion-based gel formulations , 2014, Drug delivery.

[112]  J. Heitman,et al.  Unisexual and Heterosexual Meiotic Reproduction Generate Aneuploidy and Phenotypic Diversity De Novo in the Yeast Cryptococcus neoformans , 2013, PLoS biology.

[113]  M. Castanheira,et al.  Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[114]  David W. Denning,et al.  Hidden Killers: Human Fungal Infections , 2012, Science Translational Medicine.

[115]  M. Sachs,et al.  The Antidepressant Sertraline Provides a Promising Therapeutic Option for Neurotropic Cryptococcal Infections , 2012, Antimicrobial Agents and Chemotherapy.

[116]  M. Falagas,et al.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[117]  Y. Oh,et al.  Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[118]  Daniel S. Palacios,et al.  Amphotericin primarily kills yeast by simply binding ergosterol , 2012, Proceedings of the National Academy of Sciences.

[119]  T. Horii,et al.  In Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds , 2011, Antimicrobial Agents and Chemotherapy.

[120]  Wenzhong Zhou,et al.  Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids. , 2011, Colloids and surfaces. B, Biointerfaces.

[121]  G. Boucher,et al.  Regulation of Efflux Pump Expression and Drug Resistance by the Transcription Factors Mrr1, Upc2, and Cap1 in Candida albicans , 2011, Antimicrobial Agents and Chemotherapy.

[122]  Bing Gu,et al.  Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles , 2011, Journal of drug targeting.

[123]  B. Maigret,et al.  Comparative genomics allowed the identification of drug targets against human fungal pathogens , 2011, BMC Genomics.

[124]  S. Katiyar,et al.  Mutational Analysis of Flucytosine Resistance in Candida glabrata , 2010, Antimicrobial Agents and Chemotherapy.

[125]  J. Perfect,et al.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[126]  M. Pfaller,et al.  Activity of MGCD290, a Hos2 Histone Deacetylase Inhibitor, in Combination with Azole Antifungals against Opportunistic Fungal Pathogens , 2009, Journal of Clinical Microbiology.

[127]  L. Cowen.  Hsp90 Orchestrates Stress Response Signaling Governing Fungal Drug Resistance , 2009, PLoS pathogens.

[128]  A. Madgulkar,et al.  Preparation and Evaluation of Miconazole Nitrate-Loaded Solid Lipid Nanoparticles for Topical Delivery , 2009, AAPS PharmSciTech.

[129]  K. Wannemuehler,et al.  Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS , 2009, AIDS.

[130]  P. Aeed,et al.  Inhibition of Inositol Phosphorylceramide Synthase by the Cyclic Peptide Aureobasidin A , 2009, Antimicrobial Agents and Chemotherapy.

[131]  Jie Ren,et al.  Preparation and Therapeutic Efficacy of Polysorbate-80-Coated Amphotericin B/PLA-b-PEG Nanoparticles , 2009, Journal of biomaterials science. Polymer edition.

[132]  Hiten D. Madhani,et al.  Systematic Genetic Analysis of Virulence in the Human Fungal Pathogen Cryptococcus neoformans , 2008, Cell.

[133]  M. Friedrich,et al.  Epidemiological trends in skin mycoses worldwide , 2008, Mycoses.

[134]  H. Sandovsky-Losica,et al.  Antifungal activity against Candida albicans of nikkomycin Z in combination with caspofungin, voriconazole or amphotericin B. , 2008, The Journal of antimicrobial chemotherapy.

[135]  J. Graybill,et al.  Fungicidal versus Fungistatic: what's in a word? , 2008, Expert opinion on pharmacotherapy.

[136]  La-mei Chen,et al.  Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations. , 2008, The Journal of antimicrobial chemotherapy.

[137]  H. Kristensen,et al.  Therapeutic potential of antifungal plant and insect defensins. , 2007, Drug discovery today.

[138]  J. Lodge,et al.  Chitosan, the Deacetylated Form of Chitin, Is Necessary for Cell Wall Integrity in Cryptococcus neoformans , 2007, Eukaryotic Cell.

[139]  D. Andes,et al.  Pharmacology of Systemic Antifungal Agents , 2006 .

[140]  D. Perlin,et al.  Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. , 2006, The Journal of antimicrobial chemotherapy.

[141]  Koji Yamada,et al.  IPC synthase as a useful target for antifungal drugs. , 2004, Current drug targets. Infectious disorders.

[142]  L. Tabernero,et al.  Molecular Mechanisms of Primary Resistance to Flucytosine in Candida albicans , 2004, Antimicrobial Agents and Chemotherapy.

[143]  D. Howard.  Iron gathering by zoopathogenic fungi. , 2004, FEMS immunology and medical microbiology.

[144]  H. Bussey,et al.  Large‐scale essential gene identification in Candida albicans and applications to antifungal drug discovery , 2003, Molecular microbiology.

[145]  D. Pryde,et al.  Antifungal activity of selective serotonin reuptake inhibitors attributed to non-specific cytotoxicity. , 2003, The Journal of antimicrobial chemotherapy.

[146]  J. Schlatter,et al.  Azole fungicides affect mammalian steroidogenesis by inhibiting sterol 14 alpha-demethylase and aromatase. , 2002, Environmental health perspectives.

[147]  A. Casadevall,et al.  Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C. neoformans. , 2001, Genes & development.

[148]  P. Cahn,et al.  Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS. , 2000, Medical mycology.

[149]  E. Weinberg,et al.  Iron loading and disease surveillance. , 1999, Emerging infectious diseases.

[150]  T. Inoue,et al.  Syntheses of antifungal aureobasidin A analogs with alkyl chains for structure-activity relationship. , 1998, The Journal of antibiotics.

[151]  F. Bonina,et al.  Vehicle effects on in vitro heparin release and skin penetration from different gels , 1994 .

[152]  K. Takesako,et al.  Biological properties of aureobasidin A, a cyclic depsipeptide antifungal antibiotic. , 1993, The Journal of antibiotics.

[153]  J. Adrio,et al.  Antifungals , 2017, Reactions Weekly.

[154]  M. Chorilli,et al.  Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy? , 2016, International journal of nanomedicine.

[155]  S. Free.  Fungal cell wall organization and biosynthesis. , 2013, Advances in genetics.

[156]  M. Rai,et al.  Silver nanoparticles as a new generation of antimicrobials. , 2009, Biotechnology advances.

[157]  N. K. Jain,et al.  Polypropylene imine dendrimer mediated solubility enhancement: effect of pH and functional groups of hydrophobes. , 2007, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[158]  N. Gow,et al.  Antifungal agents: mechanisms of action. , 2003, Trends in microbiology.

[159]  C Scully,et al.  Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. , 1995, The Journal of antimicrobial chemotherapy.